Gaudet, Daniel
Stevenson, Michael
Komari, Nelly
Trentin, Grace
Crowson, Caroline
Hadker, Nandini
Bernard, Sophie
Funding for this research was provided by:
Akcea Therapeutics (NA)
Article History
Received: 31 October 2019
Accepted: 28 May 2020
First Online: 2 June 2020
Ethics approval and consent to participate
: The study was approved by the institutional review board of the University of Mississippi. All study participants provided written informed consent.
: Not applicable.
: Daniel Gaudet has been involved in several clinical trials targeting the FCS population including volanesorsen and is a consultant or serves on scientific advisory board for private or public partners involved in FCS research, including Akcea, Arrowhead, the Canadian National Research Council, ECOGENE-21, Ionis, Regeneron and University of Pennsylvania. M. Stevenson, G. Trentin, and N. Komari are employees of Akcea Therapeutics. C. Crowson and N. Hadker are employees of TRINITY. Sophie Bernard reports grants from Akcea Therapeutics during the conduct of the study, grants and personal fees from Akcea Therapeutics, Amgen, The Medicine Company, Sanofi, Boehringer Ingelheim, Mark and Novo-Nordisk outside of the submitted work.